HCPConnect
For HCPs Only
Recent Clinical Updates
Loading latest clinical updates
SUSPENSION

FDA Drug Reference

Megestrol Acetate

Dosage Form

SUSPENSION

Route

ORAL

NDC

81033-150

This page summarizes official FDA drug label records for professional reference. Verify prescribing decisions against the complete current label and institutional policy.

Label Record Status

Data from U.S. Food and Drug Administration label records. Listing expiration: Date unavailable

Clinical Pharmacology

Indications & Usage

Megestrol Acetate is listed as a SUSPENSION formulation in the SUSPENSION category. Consult official FDA labeling for full prescribing information.

Administration Context

Megestrol Acetate is administered via the ORAL route as a SUSPENSION.

Administration Protocol

Prescribing Information

Refer to official FDA labeling or institutional protocols for complete dosage and administration instructions.

Safety Profile

Contraindications & Warnings

Consult the official FDA-approved labeling for complete contraindications, warnings, precautions, and patient-specific safety information.

National Drug Registry

Product and label metadata.

Marketing Category

ANDA

Route of Administration

ORAL

National Drug Code

81033-150

Manufacturer / Labeler

Kesin Pharma Corporation

Dosage Form

SUSPENSION

Strength

See labeling

Application Number

ANDA075671

SPL Identifier

3bc8709e-e70c-fc91-e063-6294a90a0e30

WHO Regulatory Intelligence

Vaccine Safety Information

Access evidence-based safety data and clinical guidelines from global health resources.

View Vaccine Safety